ACETYLCHOLINERGIC AND COMBINATION THERAPY FOR ALZHEIMER'S DISEASE
K.V. Shevtsova, V.V. Zakharov
For quotation:
Shevtsova K.V., Zakharov V.V. Acetylcholinergic and combination therapy for Alzheimer's disease.
Behavioral neuroscience. 2023; (1): 32–38.
DOI 10.46393/27129675_2023_1_32
Annotation:
The prevalence of Alzheimer's disease (AD) is increasing every year. The number of patients is expected to increase to 152 million by 2050. Currently, the main drugs for symptomatic treatment of cognitive and behavioral disorders in AD are acetylcholinesterase inhibitors (primarily donepezil) and the N-methyl-D-aspartate receptor antagonist memantine. Combination therapy with donepezil and memantine showed the greatest effectiveness in correcting cognitive functions, improving daily activity,
behavioral and mental disorders. The article discusses the problems of compliance of patients with moderate and severe dementia in AD. According to the literature, combination therapy increases adherence to therapy by 26% compared to taking two or more single drugs. A clinical case of presenile asthma with moderate degree of dementia is presented. The advantages of combination therapy in patients with early
the beginning of BA.
Journal "Behavioral Neuroscience" No. 1_2023
https://drive.google.com/file/d/1DcvRzvfInGM82jUx6ifsf1A34eGxk4CQ/view
K.V. Shevtsova, V.V. Zakharov
For quotation:
Shevtsova K.V., Zakharov V.V. Acetylcholinergic and combination therapy for Alzheimer's disease.
Behavioral neuroscience. 2023; (1): 32–38.
DOI 10.46393/27129675_2023_1_32
Annotation:
The prevalence of Alzheimer's disease (AD) is increasing every year. The number of patients is expected to increase to 152 million by 2050. Currently, the main drugs for symptomatic treatment of cognitive and behavioral disorders in AD are acetylcholinesterase inhibitors (primarily donepezil) and the N-methyl-D-aspartate receptor antagonist memantine. Combination therapy with donepezil and memantine showed the greatest effectiveness in correcting cognitive functions, improving daily activity,
behavioral and mental disorders. The article discusses the problems of compliance of patients with moderate and severe dementia in AD. According to the literature, combination therapy increases adherence to therapy by 26% compared to taking two or more single drugs. A clinical case of presenile asthma with moderate degree of dementia is presented. The advantages of combination therapy in patients with early
the beginning of BA.
Journal "Behavioral Neuroscience" No. 1_2023
https://drive.google.com/file/d/1DcvRzvfInGM82jUx6ifsf1A34eGxk4CQ/view
